Cargando…
Treatment of OPG-deficient mice with WP9QY, a RANKL-binding peptide, recovers alveolar bone loss by suppressing osteoclastogenesis and enhancing osteoblastogenesis
Osteoblasts express two key molecules for osteoclast differentiation, receptor activator of NF-κB ligand (RANKL) and osteoprotegerin (OPG), a soluble decoy receptor for RANKL. RANKL induces osteoclastogenesis, while OPG inhibits it by blocking the binding of RANKL to RANK, a cellular receptor of RAN...
Autores principales: | Ozaki, Yuki, Koide, Masanori, Furuya, Yuriko, Ninomiya, Tadashi, Yasuda, Hisataka, Nakamura, Midori, Kobayashi, Yasuhiro, Takahashi, Naoyuki, Yoshinari, Nobuo, Udagawa, Nobuyuki |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5609750/ https://www.ncbi.nlm.nih.gov/pubmed/28937990 http://dx.doi.org/10.1371/journal.pone.0184904 |
Ejemplares similares
-
Propofol attenuates osteoclastogenesis by lowering RANKL/OPG ratio in mouse osteoblasts
por: Lee, Do-Won, et al.
Publicado: (2018) -
A Jak1/2 inhibitor, baricitinib, inhibits osteoclastogenesis by suppressing RANKL expression in osteoblasts in vitro
por: Murakami, Kohei, et al.
Publicado: (2017) -
Stimulation of Bone Formation in Cortical Bone of Mice Treated with a Receptor Activator of Nuclear Factor-κB Ligand (RANKL)-binding Peptide That Possesses Osteoclastogenesis Inhibitory Activity
por: Furuya, Yuriko, et al.
Publicado: (2013) -
Serum RANKL, osteoprotegerin (OPG), and RANKL/OPG ratio in nephrotic children
por: Wasilewska, Anna, et al.
Publicado: (2010) -
From discovery of RANKL to clinical application of anti-human RANKL antibody
por: Yasuda, Hisataka, et al.
Publicado: (2012)